#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic lymphocytic leukaemia recurrent Ichthyosis Infective uveitis Macular telangiectasia Pulmonary fibrosis Mucopolysaccharidosis I Thalassaemia beta Selective polysaccharide antibody deficiency Oesophageal adenocarcinoma stage III Nodal marginal zone B-cell lymphoma Chronic cutaneous lupus erythematosus Gastric cancer Epidermolysis bullosa Philadelphia positive acute lymphocytic leukaemia Neuroendocrine tumour More trials…

    Learn about Rare Diseases

    Gaucher’s disease type I – Treatment Ewing’s sarcoma – Trials in Disease Biotinidase deficiency – Basic Information Rosai-Dorfman syndrome – Life with Disease Angiosarcoma metastatic – Life with Disease Short-bowel syndrome – Diagnostics Stevens-Johnson syndrome – Life with Disease Nephrotic syndrome – Life with Disease Hairy cell leukaemia – Trials in Disease Pleural mesothelioma malignant More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dexamethasone Phosphate Vesleteplirsen Cloxacillin Gen1055 BLEXIMENIB Jab-21822 Sulfamethoxazole Apremilast Gskvx000000008866 Terbinafine Hydrochloride Plerixafor Exemestane Fenofibrate Micronised Trometamol ARI0008 Milrinone Bleomycin Sulfate Amantadine Hydrochloride Cevostamab RUBIDIUM CHLORIDE More therapies…

    Learn about Your Condition

    Device related infection Von Hippel-Lindau disease Peritonitis Tooth loss Tympanic membrane hyperaemia Nasopharyngeal cancer Pneumothorax Propionic acidaemia CDKL5 deficiency disorder Basal cell carcinoma Mesothelioma Nephrolithiasis Meniscus injury Astrocytoma malignant Hypercholesterolaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Iberdomide
    • Bortezomib
    • Daratumumab
    Austria Belgium Czechia Denmark Finland France +10

  • Study on Isatuximab and Dexamethasone for Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplantation

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    • Dexamethasone Sodium Phosphate
    Italy

  • Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Isatuximab
    • Bortezomib
    • Dexamethasone
    Germany

  • Study on Early Treatment with Teclistamab and Talquetamab for Patients with Newly Diagnosed High-Risk Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Talquetamab
    • Teclistamab
    • Bortezomib
    Spain

  • Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Melphalan
    • Bortezomib
    • Daratumumab
    Italy

  • Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Carfilzomib
    • Dexamethasone Sodium Phosphate
    • Lenalidomide
    Italy
Previous Page
1 … 11 12 13 14 15 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!